# **Murine IL-4 ELISA Kit**

_	_	_	
1 4	uctions	£	
inetri	ICTIONS	TOT	IICA
поп	มนเบเจ	IUI	usc

Catalogue numbers: 1x96 tests: 660 020 096

# For research use only

Fast Track Your Research.....

# **Table of Contents**

1.	Intended use	2
2.	Introduction	2
2.1.	Summary	2
2.2.	Principle of the method	2
3.	Reagents provided and reconstitution	3
4.	Materials required but not provided	3
5.	Storage Instructions	3
6.	Specimen collection, processing & storage	4
7.	Safety & precautions for use	4
8.	Assay Preparation	5
8.1.	Assay Design	5
8.2.	Preparation of Wash Buffer	5
8.3.	Preparation of Assay Buffer	5
8.4.	Preparation of Standard	6
8.5.	Preparation of Biotin Conjugate	6
8.6.	Preparation of Streptavidin-HRP	6
9.	Method	7
10.	Data Analysis	8
11.	Assay limitations	8
12.	Performance Characteristics	8
12.1.	. Sensitivity	9
12.2.	. Specificity	9
12.3.	. Precision	9
12.4.	Dilution Parallelism	9
12.5.	. Spike Recovery	9
12.6.	. Stability	9
12.7	Expected values	9
12.8.	. Standard Calibration	9
13.	Bibliography	10
14.	Assay Summary	11

# Murine IL-4 ELISA Kit

#### 1. Intended use

The murine IL-4 ELISA is an enzyme-linked immunosorbent assay for quantitative detection of murine Interleukin-4 (mIL-4) in cell culture supernatants, murine serum, plasma or other body fluids.

This kit has been configured for research use only. Not suitable for use in therapeutic procedures.

## 2. Introduction

### 2.1. Summary

IL-4 mediates ist function by binding to receptors expressed on target cells. The IL-4 receptors exhibit an affinity of approximately 10<sup>-10</sup> M (17).

Receptors exist on freshly prepared B and T lymphocytes and macrophages, as well as on various cell lines including lymphoid cells, mast cell lines, a variety of other hematopoietic cell lines, fibroblasts and stromal cell lines (10, 13, 15). On T and B cells, receptors are present in low numbers (appr. 400), which are reported to be upregulated by IL-2 and IL-4 (4, 12, 14).

IL-4 is produced by a particular subset of T helper cells, the  $T_{H2}$  cells. These cells tend to make a specific set of lymphokines including IL-4, IL-5, IL-6, IL-10, IL-13 and GM-CSF and fail to produce IL-2, IFN $\gamma$ , and lymphotoxin (TNF $\beta$ ) (17). Apart from T cells, it has been shown that mast cells can produce IL-4 (18).

IL-4 exerts numerous effects on various hematopoietic cell types. On B cells, IL-4 promotes immunological class switching to IgE and  $IgG_1$  isotypes and upregulates MHC class II and CD23 expression (2, 8). It can promote survival, growth, and differentiation of both T and B lymphocytes (1, 3, 5), mast cells (6, 11), and endothelial cells.

In addition, IL-4 can inhibit the production of TNF, IL-1, and IL-6 by macrophages (7, 9).

## 2.2. Principle of the method

An anti-murine IL-4 coating antibody is adsorbed onto microwells. Murine IL-4 present in the sample or standard binds to antibodies adsorbed to the microwells. A biotin-conjugated anti-murine IL-4 antibody is added and binds to murine IL-4 captured by the first antibody.

Following incubation unbound biotin-conjugated anti-murine IL-4 antibody is removed during a wash step. Streptavidin-HRP is added and binds to the biotin-conjugated anti-murine IL-4 antibody. Following incubation unbound Streptavidin-HRP is removed during a wash step, and substrate solution reactive with HRP is added to the wells.

A coloured product is formed in proportion to the amount of murine IL-4 present in the sample or standard. The reaction is terminated by addition of acid and absorbance is measured at 450 nm.

# 3. Reagents provided and reconstitution

REAGENTS (store at 2-8°C)	Quantity 1x96 well kit 660.020.096	RECONSTITUTION
96-well precoated microtiter plate	1	Ready-to-use
Plate covers	2	
Biotin-Conjugate anti-mouse IL-4 monoclonal antibody	1 vial	Dilute 100 times in Assay Buffer (70µl)
Streptavidin-HRP	1 vial	Dilute 200 times in Assay Buffer (150µl)
mIL-4 Standard	2 vials	Reconstitute as indicated on the vial
Assay Buffer Concentrate	1 vial	(5 ml) 20X concentrate. Dilute in distilled water
Wash Buffer Concentrate	1 vial	(50 ml) 20X concentrate. Dilute in distilled water
Sample Diluent	1 vial	(12 ml)
Substrate Solution	1 vial	(15 ml) Ready-to-use
Stop Solution (1M Phosphoric acid)	1 vial	(15 ml) Ready-to-use

# 4. Materials required but not provided

- Microtiter plate reader fitted with appropriate filters (450nm required with optional 630nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 50-300µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- · Miscellaneous laboratory plastic and/or glass, if possible sterile

# 5. Storage Instructions

Store kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the kit and reagents is stated on box front labels.

The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

**Wash buffer 1X:** Once prepared, store at 2-8°C for up to 30 days. **Assay Buffer 1X:** Once prepared, store at 2-8°C for up to 30 days.

# 6. Specimen collection, processing & storage

Cell culture supernatants, serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

**Cell culture supernatants**: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

**Storage**: If not analyzed shortly after collection, samples should be aliquoted (250-500µI) to avoid repeated freeze-thaw cycles and stored frozen at -70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

**Recommendation:** Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

# 7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g.CDC/NIH Health manual : "Biosafety in Microbiological and Biomedical Laboratories" 1984
- Laboratory gloves should be worn at all times
- Avoid any skin contact with Stop Solution and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of Stop Solution and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- · Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate

# 8. Assay Preparation

Bring all reagents to room temperature before use

## 8.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**. Remove sufficient Microwell Strips for testing from the aluminium pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

**Example plate layout** (example shown for a 6 point standard curve)

	Stand	dards		Sample Wells								
	1	2	3	4	5	6	7	8	9	10	11	12
Α	250	250										
В	125	125										
С	62.5	62.5										
D	31.3	31.3										
E	15.6	15.6										
F	7.8	7.8										
G	0	0										
Н												

All remaining empty wells can be used to test samples in duplicate

## 8.2. Preparation of Wash Buffer

If crystals have formed in the Wash Buffer Concentrate, warm it gently until they have completely dissolved.

Pour entire contents (50 ml) of the **Wash Buffer** Concentrate into a clean 1,000 ml graduated cylinder. Bring final volume to 1,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. The pH of the final solution should adjust to 7.4. Transfer to a clean wash bottle and store at 2°C to 8°C.

#### 8.3. Preparation of Assay Buffer

Mix the contents of the bottle well.

Add contents of **Assay Buffer** Concentrate (5.0 ml) to 95 ml distilled or deionized water and mix gently to avoid foaming. Store at 2° to 8°C.

#### 8.4. Preparation of Standard

Standard vials must be reconstituted with the volume of distilled water shown on the vial immediately prior to use. This reconstitution gives a stock solution of 500pg/ml of mlL-4. **Mix the reconstituted standard gently by inversion only**. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 250 to 7.8 pg/ml. A fresh standard curve should be produced for each new assay.

- Add 100 µl of Sample Diluent to all standard and blank wells
- Immediately after reconstitution add 100µl of the reconstituted standard to well's A1 and A2, which provides the highest concentration standard at 250pg/ml. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100μl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 250 to 7.8 pg/ml
- Discard 100μl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred directly into the relevant wells.

## 8.5. Preparation of Biotin Conjugate

Make a 1:100 dilution with Assay Buffer (1X) in a clean plastic tube as needed according to the following table:

Number	Biotin-	Assay	
of Strips	Conjugate (μΙ)	Buffer (ml)	
1 - 6	30	2.97	
1 - 12	60	5.94	

#### 8.6. Preparation of Streptavidin-HRP

Make a 1:200 dilution of the concentrated **Streptavidin-HRP** solution in Assay Buffer (1X) as needed according to the following table:

Number	Streptavidin-HRP	Assay	
of Strips	(µI)	Buffer (ml)	
1 - 6	30	5.97	
1 - 12	60	11.94	

## 9. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vial which must be mixed gently by inversion only.

Prepare all reagents as shown in section 8.

Note: final preparation of Biotin conjugate (section 8.5) and Streptavidin-HRP (section 8.6) should occur immediately before use.

Assay Step		Details			
1.	Wash	Remove the pre-coated plate from the sealed pouch, removed any un-needed strips and wash the plate as follows:  a) Dispense 0.3 ml of <b>1x washing solution</b> into each well b) Aspirate the contents of each well c) Repeat step a and b			
2.	Addition	Prepare <b>Standard curve</b> as shown in section 8.4 above			
3.	Addition	Add 100µl of <b>Sample Diluent</b> in duplicate to the blank wells			
4.	Addition	Add 50μl of <b>Sample Diluent</b> to the sample wells			
5.	Addition	Add 50μl of each <b>Sample</b> in duplicate to the designated wells			
6.	Addition	Add 50μl of diluted <b>Biotin Conjugate</b> to all wells including blanks			
7.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for <b>2 hours</b> on a rotator set at 200rpm if available			
8.	Wash	Remove the cover and wash the plate as follows:  a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times			
9.	Addition	Add 100μl of diluted <b>Streptavidin-HRP</b> solution into all wells			
10.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for <b>1 hour</b> on a rotator set at 200rpm if available			
11.	Wash	Repeat wash step 8.			
12.	Addition	Add 100μl of ready-to-use <b>TMB Substrate Solution</b> into all wells			
13.	Incubation	Incubate for 1 <b>0 minutes</b> * at room temperature on a rotar set at 200rpm if available. Avoid direct exposure to light by wrapping the plate in aluminium foil			
14.	Addition	Add 100μl of <b>Stop Reagent</b> into all wells			
Read	Read the absorbance value of each well (immediately after step 14.) on a spectrophotometer using				

**Read the absorbance** value of each well (immediately after step 14.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).

<sup>\*</sup>Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range

# 10. Data Analysis


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding mIL-4 standard concentration on the horizontal axis.

The amount of mIL-4 in each sample is determined by extrapolating OD values against mIL-4 standard concentrations using the standard curve.

## **Example mIL-4 Standard Curve**

Standard	mIL-4 Conc	OD (450nm) mean	CV (%)
1	250	1.985	0.4
2	125	1.113	1.7
3	62.5	0.614	0.7
4	31.3	0.331	3.5
6	15.6	0.212	0.7
7	7.8	0.121	1.2
Zero	0	0.040	-



**Note**; curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For samples which have been diluted according to the protocol (1:2), the calculated concentration should be multiplied by the dilution factor.

# 11. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore a fresh standard curve must be prepared and run for every assay

### 12. Performance Characteristics

## 12.1. Sensitivity

The limit of detection of mIL-4 defined as the analyte concentration resulting in an absorption significantly higher than that of the dilution medium (mean plus three standard deviations) was determined to be 2.0 pg/ml (mean of 6 independent assays).

## 12.2. Specificity

The interference of circulating factors of the immune systems was evaluated by spiking these proteins at physiologically relevant concentrations into a mIL-4 positive serum. There was no detectable cross reactivity.

#### 12.3. Precision

#### Intra-assay

Reproducibility within the assay was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing different concentrations of mouse IL-4. 2 standard curves were run on each plate. The overall intra-assay coefficient of variation has been calculated to be <5%.

#### Inter-assay

Assay to assay reproducibility within one laboratory was evaluated in 3 independent experiments. Each assay was carried out with 6 replicates of 8 serum samples containing differents concentrations of mouse IL-4. 2 standard curves were run on each plate. The overall inter-assay coefficient of variation has been calculated to be <10%.

#### 12.4. Dilution Parallelism

Murine serum spiked with different levels of mIL-4 was assayed at four serial twofold dilutions with 4 replicates each. Experiments showed an **overall mean recovery of 120 %.** 

#### 12.5. Spike Recovery

The spike recovery was evaluated by spiking four levels of mIL-4 into pooled normal murine serum. Recoveries were determined in two independent experiments with 4 replicates each. Observed values showed an **overall mean recovery of 87%.** 

#### 12.6. Stability

## **Storage Stability**

Aliquots of spiked serum were stored at -20°C, 2-8°C, room temperature (RT) and at 37°C, and the mIL-4 level determined after 24 h. There was no significant loss of mIL-4 immunoreactivity during storage at -20°C, 4°C and room temperature. A significant loss of mIL-4 immunoreactivity (50%) was detected during storage at 37°C after 24 hours.

#### Freeze-thaw Stability

Aliquots of spiked serum were stored frozen at -20°C and thawed up to 5 times, and mIL-4 levels determined. There was no significant loss of IL-4 by freezing and thawing up to 5 times.

#### 12.7. Expected values

There are no detectable mIL-4 levels found. Elevated mIL-4 levels depend on the type of immunological disorder.

#### 12.8. Standard Calibration

The immunoassay is calibrated with highly purified recombinant mIL-4 which has been evaluated against the international Reference Standard NIBSC 91/656 and has been shown to be equivalent. NIBSC 91/656 is quantitated in International Units (IU), 1 IU corresponding to 100pg mIL-4.

# 13. Bibliography

- 1. Brown M., J. Hu-Li, and W. E. Paul. (1988). IL-4/B cell stimulatory factor-1 stimulates T cell growth by an IL-2 independent mechanism. J. Immunol. 141, 504-511.
- 2. Coffman R. L., J. Ohara, M. W. Bond, J. Carty, A. Zlotnik, and W. E. Paul. (1986). B cell stimulatory factor-1 enhances IgE response of lipopolysaccharide-activated B cells. J. Immunol. 136, 4538-4541.
- 3. De France T., T. Vanbervliet, J. P Aubrey, et al. (1987). B cell growth promoting activity of recombinant human interleukin 4. J. Immunol. 139, 1135-1141.
- 4. Foxwell B. M. J., G. Woerly, and B. Ruffel. (1989). Identification of interleukin 4 receptor-associated proteins and expression of both high and low-affinity binding on human lymphoid cells. Eur. J. Immunol. 19, 1637-1641.
- 5. Grabstein K. H., L. S. Park, P. J. Morrisey, H. Sassenfeld, V. Price, D. L. Urdal, and M. B. Widmer. (1987). Regulation of murine T cell proliferation by B cell stimulatory factor-1. J. Immunol. 139, 1148-1153.
- 6. Hamaguchi Y, Y. Kanakura, J. Fujita, et al. (1987). Interleukin 4 as an essential factor for in vitro clonal growth of murine connective tissue-type mast cells. J. Exp. Med. 165, 268-273.
- 7. Hart P. H., G. F. Vitti, D. R. Burgess, G. A. Whitty, D. S. Piccoli, and J. A. Hamilton. (1989). Potential antiinflammatory effects of interleukin 4: suppression of human monocyte, tumour necrosis factor  $\alpha$ , interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci, USA 86, 3803-3807.
- 8. Kikutani H, S. Inui, R. Sato et al. (1986). Molecular structure of human lymphocyte receptor for immunoglobulin. Cell 47, 657-665.
- 9. Lee J. D., S. G. Swisher, E. H. Minehart, W. H. McBride, and J. S. Economou. (1990). Interleukin 4 downregulates interleukin 6 production in human peripheral blood mononuclear cells. J. Leukocyte Biol. 47, 475-479.
- 10. Lowenthal J., B. Castle, J. Schreurs, D. Rennick, N. Arai, P. Hoy, Y. Takebe, and M. Howard. (1988). Expression of high affinity receptors for interleukin 4 on hemopoietic and non-hemopoietic cells. J. Immunol. 140, 456.
- 11. Mossman T. R., M. W. Bond, R. L. Coffman, J. Ohara, and W. E. Paul. (1986). T-cell and mast cell lines respond to B-cell stimulator factor-1. Proc. Natl. Acad. Sci. USA, 5654-5658.
- 12. Puri R. K., D. S. Finbloom, P. Leland, M. Mostowski, and J. P. Siegel. (1990). Expression of high affinity IL-4 receptors on murine tumour infiltrating lymphocytes and their upregulation by IL-2. Immunol. 70, 492-497.
- 13. Ohara J., and W. E. Paul. (1987). Receptors for B-cell stimulatory factor-1 expressed on cells of hematopoietic lineage. Nature 325, 537.
- 14. Ohara J., and W. E. Paul. (1988). Upregulation of interleukin 4/B cell stimulatory factor-1 receptor expression. Proc. Natl. Acad. Sci. USA 85, 8221-8225.
- 15. Park L., D. Friend, K. Grabstein, and D. Urdal. (1987). Characterization of the high-affinity cell-surface receptor for murine B-cell stimulating factor. Proc. Natl. Acad. Sci. USA 84, 1669.
- 16. Paul W. E. (1991). Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77, 1859-1870.
- 17. Plaut M., J. H. Pierce, C. J. Watson, J. Hanley-Hyde, R. P. Nordan, and W. E. Paul. (1989). Mast cell lines produce lymphokines in response to cross linkage of FC<sub>E</sub>R1 or to calcium ionophores. Nature 339, 64-67.
- 18. Roehm N. W., H. J. Leibson, A. Zlotnik, J. Kappler, P. Marrack, and J. Cambier. (1984). Interleukin-induced increase in la expression by normal mouse B cells. J. Exp. Med. 160, 679-694.

# 14. Assay Summary

Total procedure length: 3h10mn

 ${\bf Add\ Sample\ Diluent,\ Sample\ ,\ Standard\ and\ Biotin\ Conjugate}$ 

Incubate 2 hours at room temperature

Wash three times

Add 100µl of Streptavidin-HRP

Incubate 1 hour at room temperature  $\downarrow$ 

Wash three times  $_{\downarrow}$ 

Add 100  $\mu l\,$  of ready-to-use TMB Protect from light. Let the color develop for 10 mn.

Add 100 μl Stop Reagent

Read Absorbance at 450 nm

# Supplier:

Diaclone SAS 6 Rue Dr Jean-François-Xavier Girod 25000 Besançon France

Tel +33 (0)3 81 41 38 38

Email: techsupport@medixbiochemica.com